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The eukaryotic inward rectifier potassium 
(Kir) channel family is part of an ancient 
class of ion channels evolved in prokaryotes 
(Durell and Guy, 2001). Kir proteins have 
two transmembrane domains encompassing 
the pore loop region. Subunit tetrameriza-
tion, either homo- or hetero-typic, results in 
the formation of a functional channel. The 
16 known mammalian Kir channel proteins 
are divided over seven different families, 
each having their own specific expression 
pattern and functional characteristics (De 
Boer et al., 2010; Hibino et al., 2010). In gen-
eral, Kir channels allow more inward potas-
sium flow at membrane potentials negative 
from the potassium equilibrium potential 
(E
K
) than outward flow at equivalent mem-
brane potentials positive of E
K
, a character-
istic known as inward rectification. Within 
the superfamily, strong and weak rectifiers 
exist. Strong rectifying channels are most 
apparent in excitable tissues, where they are 
responsible for a stable and negative rest-
ing membrane potential, and due to their 
strong rectification, prevent extensive potas-
sium loss during action potential formation. 
Weak rectifiers are expressed in numerous 
other tissue types and organs and have a 
role in processes like potassium homeo-
stasis, insulin release, and signal transduc-
tion. Despite the long evolutionary history 
only a few inhibitors are known, of which 
most show limited specificity at their best. 
One of the most widely used Kir inhibitors 
is Ba2+. However, as it blocks all Kir chan-
nels at concentrations differing not even 
two orders of magnitude, its severe effects 
in whole animal studies or poisoning cases 
are difficult to ascribe to a given Kir family 
member (De Boer et al., 2010). Given the 
fact that most cell types express more than 
one Kir channel protein, lack of specific 
inhibitors therefore strongly hinders our 
understanding of their contribution and 
working mechanism in normal physiology 
and pathology. The presence of disease caus-
ing mutations in human Kir channels that 
lead to severe syndromes, e.g., Bartter’s syn-
drome (Kir1.1), Andersen Tawil syndrome 
(Kir2.1), SeSAME syndrome (Kir4.1), 
neonatal diabetes (Kir6.2), Snowflake vit-
reoretinal degeneration (Kir7.1) illustrate 
their importance in human pathology, 
while many more milder Kir related chan-
nelopathies probably remain unaccounted 
for at this moment. An excellent illustration 
of the potential of inward rectifier channel 
inhibitors comes from the field of neonatal 
diabetes where recognition of disease caus-
ing gain-of-function mutations in Kir6.2 
(Gloyn et al., 2004) and its regulatory subu-
nit Sur1 (Ellard et al., 2007) provided new 
insights to treat the disease with Kir6/Sur 
inhibitors (Pearson et al., 2006). One of the 
diseases that affects significant numbers of 
the aging human population, and has been 
correlated to Kir2.X and Kir3.X dysfunction, 
is atrial fibrillation. Increased Kir channel 
activity in the atria shortens atrial action 
potential durations and thereby allows 
formation of multiple re-entry circuits in 
the atrial tissue fueling rapid arrhythmia. 
Furthermore, ventricular Kir2.1 overex-
pression in mice results in rotor driven 
tachycardia’s. These mechanisms are likely 
to have a role in initiation and perpetuation 
of the process of atrial fibrillation. Therefore, 
pharmacological intervention by means of 
Kir channel modifying drugs may be a new 
and valuable treatment option in this disease 
(Ehrlich, 2008).
Standard single cell patch clamp meth-
ods allow highly detailed characterization 
of the inhibiting capacity and its underlying 
mechanisms of new compounds for virtu-
ally every ion channel of interest, including 
Kir channels. However, procedures are time 
consuming and therefore not compatible 
with large screening procedures. Automated 
patching techniques to a large extent over-
come these throughput limitations (Dunlop 
et al., 2008). Alternatively, the last decade, 
a number of non-electrophysiological Kir 
assay systems have been developed that allow 
large scale screening assays also. Systems are 
either based on membrane potential sen-
sitive dyes (e.g., Walsh, 2011) or thallium 
flux (e.g., Niswender et al., 2008). The latter 
makes use of a thallium sensitive fluores-
cent probe loaded into Kir expressing cells. 
Upon stimulation of channel opening, thal-
lium from the bath medium enters the cell 
through Kir channels, resulting in increased 
fluorescence. Co-application of different 
test compounds to the bath medium than 
enables identification of potent Kir channel 
inhibitors, and dependent on the assay con-
ditions, activators. New lead compounds for 
every Kir class will likely be derived from 
screening efforts of public, academic, or pri-
vate owned compound libraries (e.g., Wang 
et al., 2011), or from development of exist-
ing drugs displaying Kir channel block as an 
apparent side effect (Van der Heyden and 
Sánchez-Chapula, 2011).
In this issue of Frontiers in Pharmacology 
of Ion Channel and Channelopathies, 
Raphemot et al. (2011) describe the results 
from a screen for compounds that can 
inhibit Kir3.X channels. For this purpose, 
they used a thallium flux assay in combi-
nation with a compound library originally 
used for discovery of new Kir1.1 inhibitors. 
They identified a lead compound, named 
VU573 that besides blocking Kir3.X, also 
demonstrate specificity for Kir2.3 chan-
nels over Kir2.1. Subsequent cross valida-
tion using patch clamp assays in Xenopus 
oocytes and HEK293 cells reached similar 
conclusions. However, VU573 showed also 
inhibiting action on Kir7.1. Next, making 
clever use of a Kir7.1 mutant, they developed 
and validated a Kir7.1 thallium flux assay, 
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and in combination with a medicinal chem-
istry approach, this yielded a VU573 analog 
that lost affinity for Kir7.1 and Kir1.1, but 
retained reasonable inhibition of Kir3.X and 
Kir2.3. This makes an interesting combina-
tion from the perspective of atrial fibrillation 
therapy, since Kir3.1/3.4 and Kir2.3 are pre-
dicted channels involved in atrial fibrillation 
(Ehrlich, 2008) as mentioned before.
New questions are arising now. What 
is the nature of Kir inhibition by VU573? 
As pointed out by the authors, drugs can 
directly plug the channel pore inhibiting 
potassium flow, interfere with lipid [i.e., 
phosphatidylinositol 4,5-bisphosphate 
(PIP
2
)] dependent Kir activation or both. 
The preference of VU573 for Kir2.3 over 
Kir2.1 might indicate a role for PIP
2
 inter-
ference, but extensive studies using channel 
structure models, Kir mutations affecting 
PIP
2
 binding, and application of PIP
2
 during 
patch clamp experiments are required first 
to answer this intriguing question. Secondly, 
what is the long term effect of VU573 or 
its derivatives on ion channel trafficking? 
An increasing number of drugs, regardless 
whether they block the channel directly, 
affect channel protein trafficking result-
ing in decreased amounts of functional 
channels on the plasma membrane which 
may pose an arrhythmogenic risk (Van der 
Heyden et al., 2008). Thirdly, is a combined 
Kir3.X and Kir2.3 block effective indeed 
against atrial fibrillation without affecting 
ventricular electrophysiological parame-
ters? Dedicated in vitro and in vivo models 
are essential here to answers these questions.
The data reported by Raphemot et al. 
(2011) are another step in the development 
of subtype specific I
K1
 modifiers that even-
tually will provide valuable insights into 
the roles of I
K1
 in normal physiology and 
may offer clinicians new treatment options 
for a diverse set of genetic syndromes and 
acquired diseases.
Acknowledgments
I thank Dr. T. P. de Boer for careful reading 
of the manuscript. This work was supported 
by a grant from the Dondersfonds (Utrecht, 
The Netherlands).
RefeRences
De Boer, T. P., Houtman, M. J. C., Compier, M., and Van 
der Heyden, M. A. G. (2010). The mammalian KIR2.x 
inward rectifier ion channel family: expression pat-
tern and pathophysiology. Acta Physiol. (Oxf.) 199, 
243–256.
Dunlop, J., Bowlby, M., Peri, R., Vasilyev, D., and Arias, 
R. (2008). High-throughput electrophysiology: an 
emerging paradigm for ion-channel screening and 
physiology. Nat. Rev. Drug Discov. 7, 358–368.
Durell, S. R., and Guy, H. R. (2001). A family of putative 
Kir potassium channels in prokaryotes. BMC Evol. 
Biol. 1, 14. doi: 10.1186/1471-2148-1-14
Ehrlich, J. R. (2008). Inward rectifier potassium currents 
as a target for atrial fibrillation therapy. J. Cardiovasc. 
Pharmacol. 52, 129–135.
Ellard, S., Flanagan, S. E., Girard, C. A., Patch, A. M., 
Harries, L. W., Parrish, A., Edghill, E. L., Mackay, D. 
J., Proks, P., Shimomura, K., Haberland, H., Carson, 
D. J., Shield, J. P., Hattersley, A. T., and Ashcroft, F. 
M. (2007). Permanent neonatal diabetes caused by 
dominant, recessive, or compound heterozygous 
SUR1 mutations with opposite functional effects. 
Am. J. Hum. Genet. 81, 375–382.
Gloyn, A. L., Pearson, E. R., Antcliff, J. F., Proks, P., 
Bruining, G. J., Slingerland, A. S., Howard, N., 
Srinivasan, S., Silva, J. M., Molnes, J., Edghill, E. L., 
Frayling, T. M., Temple, I. K., Mackay, D., Shield, J. 
P., Sumnik, Z., Van Rhijn, A., Wales, J. K., Clark, P., 
Gorman, S., Aisenberg, J., Ellard, S., Njølstad, P. R., 
Ashcroft, F. M., and Hattersley, A. T. (2004). Activating 
mutations in the gene encoding the ATP-sensitive 
potassium-channel subunit Kir6.2 and permanent 
neonatal diabetes. N. Engl. J. Med. 350, 1838–1849.
Hibino, H., Inanobe, A., Furutani, K., Murakami, S., 
Findlay, I., and Kurachi, Y. (2010). Inwardly  rectifying 
potassium channels: their structure, function, and 
physiological roles. Physiol. Rev. 90, 291–366.
Niswender, C. M., Johnson, K. A., Luo, Q., Ayala, J. E., 
Kim, C., Conn, P. J., and Weaver, C. D. (2008). A novel 
assay of Gi/o-linked G protein-coupled receptor cou-
pling to potassium channels provides new insights 
into the pharmacology of the group III metabotropic 
glutamate receptors. Mol. Pharmacol. 73, 1213–1224.
Pearson, E. R., Flechtner, I., Njølstad, P. R., Malecki, M. 
T., Flanagan, S. E., Larkin, B., Ashcroft, F. M., Klimes, 
I., Codner, E., Iotova, V., Slingerland, A. S., Shield, J., 
Robert, J. J., Holst, J. J., Clark, P. M., Ellard, S., Søvik, 
O., Polak, M., Hattersley, A. T., and Neonatal Diabetes 
International Collaborative Group. (2006). Switching 
from insulin to oral sulfonylureas in patients with 
diabetes due to Kir6.2 mutations. N. Engl. J. Med. 
355, 467–477.
Van der Heyden, M. A. G., and Sánchez-Chapula, J. A. 
(2011). Toward specific cardiac IK1 modulators for 
in vivo application: old drugs point the way. Heart 
Rhythm 8, 1076–1080.
Van der Heyden, M. A. G., Smits, M. E., and Vos, M. 
A. (2008). Drugs and trafficking of ion channels: 
a new pro-arrhythmic threat on the horizon? Br. J. 
Pharmacol. 153, 406–409.
Walsh, K. B. (2011). Targeting GIRK channels for the 
development of new therapeutic agents. Front. 
Pharmacol. 2:64. doi: 10.3389/fphar.2011.00064
Wang, H. R., Wu, M., Yu, H., Long, S., Stevens, A., Engers, D. 
W., Sackin, H., Daniels, J. S., Dawson, E. S., Hopkins, C. 
R., Lindsley, C. W., Li, M., and McManus, O. B. (2011). 
Selective inhibition of the Kir2 family of inward recti-
fier potassium channels by a small molecule probe: the 
discovery, SAR, and pharmacological characterization 
of ML133. ACS Chem. Biol. 6, 845–856.
Received: 11 November 2011; accepted: 23 December 2011; 
published online: 09 January 2012.
Citation: van der Heyden MAG (2012) Finding inward rec-
tifier channel inhibitors: why and how? Front. Pharmacol. 
2:95. doi: 10.3389/fphar.2011.00095
This article was submitted to Frontiers in Pharmacology of 
Ion Channels and Channelopathies, a specialty of Frontiers 
in Pharmacology.
Copyright © 2012 van der Heyden. This is an open-access 
article distributed under the terms of the Creative Commons 
Attribution Non Commercial License, which permits non-
commercial use, distribution, and reproduction in other 
forums, provided the original authors and source are credited.
van der Heyden Inward rectifier inhibitors
Frontiers in Pharmacology | Pharmacology of Ion Channels and Channelopathies January 2012 | Volume 2 | Article 95 | 2
